Executive Order Accelerates Psychedelic Approvals, Sends Stock Prices Soaring

On Monday, President Donald Trump signed an executive order that formally instructs the Food and Drug Administration to issue expedited review vouchers for any psychedelic‑based therapy that has already received the agency’s breakthrough designation, thereby reducing the standard six‑to‑ten‑month review window to an ostensibly rapid one‑to‑two‑month timeframe.

Within minutes of the announcement, the equity markets responded with a pronounced enthusiasm that manifested itself in a 53 percent surge in the share price of Compass Pathways, a 37 percent jump for Atai Beckley, a 34 percent rise for GH Research, and a more modest yet still notable 16 percent climb for Definium Therapeutics, while the AdvisorShares Psychedelics ETF briefly touched its highest intraday level since July 2023 with a 20 percent increase.

All of the companies that experienced the most pronounced price appreciation happen to have already secured the FDA’s breakthrough therapy designation for their respective psychedelic programs, a status that, under the new order, automatically qualifies them for the expedited vouchers and consequently places them in a privileged regulatory lane that bypasses the longer, more deliberative assessment process traditionally applied to novel psychiatric treatments.

Critics might observe that the confluence of a presidential directive, a rapid‑track regulatory mechanism, and an immediate market reward creates a feedback loop in which the promise of faster approvals is monetized before any substantive clinical evidence of safety or efficacy has been rigorously evaluated, thereby exposing a systemic vulnerability wherein policy enthusiasm can outpace scientific prudence.

The episode also underscores a broader institutional inconsistency, namely the juxtaposition of an agency charged with safeguarding public health against the backdrop of a political imperative to accelerate access to a class of substances whose long‑term risk‑benefit profile remains incompletely characterized, a tension that the current framework appears ill‑equipped to reconcile without resorting to ad‑hoc procedural shortcuts.

As investors continue to chase the fleeting optimism generated by the order, the market’s reaction serves as a reminder that the allure of breakthrough designations can, in practice, function as a proxy for speculative hype, raising questions about whether the expedited review vouchers represent a genuine public‑health advance or merely a convenient tool for aligning regulatory timelines with capital market expectations.

Published: April 21, 2026